EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Immuno-Activated, Highly Expressing PD-1 Phenotype in Hepatocellular Carcinoma Is Associated with a Lower Recurrence Rate

Gabriel F Hess, Caner Ercan, Alexander Wilhelm, Jasmin Zeindler, Mairene Coto-Llerena, Silvio Däster, Simone Muenst, Jürg Vosbeck, Luca Di Tommaso, Martin Bolli, Luigi M Terracciano, Otto Kollmar und 2 weitere

Pathobiology · 2025

DOI: 10.1159/000543933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathobiology, 2025. Verfasst von Gabriel F Hess und 13 weiteren Autor:innen. Beteiligte Einrichtung: Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland, gabriel.hess@claruni…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Programmed Cell Death 1 Receptor, Neoplasm Recurrence, Local. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Curative treatments in early-stage hepatocellular carcinoma (HCC) are limited by high recurrence rates, and targeted therapies against HCC are rare. Tumour microenvironment (TME) plays a crucial role. One strategy is the expression of programmed cell death receptor 1 ligand (PD-L1), whose receptor PD-1 is expressed on activated T cells. The use of immune checkpoint inhibitors (ICIs) has shown antitumour activity. In HCC, ICIs are proposed as a possible first- and second-line therapy. The expression of PD-1 and PD-L1 in the TME is of prognostic importance and can predict response to ICIs. Our study aimed to investigate the impact of intratumoural PD-1 and PD-L1 expression on HCC recurrence and its relation to cancer-immune phenotypes.

Methods

Immunohistochemical staining was performed on archival tissue from 93 HCC, using the antibodies NAT105 (PD-1) and Ventana SP263 (PD-L1). Tumours were classified as immunologically active, excluded, or deserted. PD-1 and PD-L1 immunoreactivity was evaluated as the proportion of positive immune cells compared to the total immune cells (0%, 1%).

Results

HCC with PD-1 expression in >1% of immune cells had a significantly lower recurrence rate than tumours with 1% (77%; 48/62). Tumours with both characteristics had a significantly lower recurrence rate (p = 0.039).

Conclusion

PD-1 expression on immune cells is associated with a lower recurrence rate in HCC, suggesting a role in HCC recurrence. The therapeutic use of adjuvant anti-PD-1 antibodies should thus be viewed critically and investigated further.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsProgrammed Cell Death 1 ReceptorNeoplasm Recurrence, LocalB7-H1 AntigenHumansMaleMiddle AgedFemaleTumor MicroenvironmentAgedAdultPhenotypeBiomarkers, TumorAged, 80 and overPrognosisImmunohistochemistry

Stichwörter der Autor:innen

Hepatocellular carcinomaImmune-phenotypePD-1

Substanzen

Programmed Cell Death 1 ReceptorPDCD1 protein, humanB7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland, gabriel.hess@clarunis.ch.
  • Clarunis, Department of Visceral Surgery, University Centre for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital Basel, Basel, Switzerland, gabriel.hess@clarunis.ch.
  • Visceral Surgery and Precision Medicine Research Laboratory, Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
  • Clarunis, Department of Visceral Surgery, University Centre for Gastrointestinal and Liver Diseases, St. Clara Hospital and University Hospital Basel, Basel, Switzerland.
  • Faculty of Medicine, University of Basel, Basel, Switzerland.

Zitieren

APA

Hess, G. F., Ercan, C., Wilhelm, A., Zeindler, J., Coto-Llerena, M., Däster, S., Muenst, S., Vosbeck, J., Di Tommaso, L., Bolli, M., Terracciano, L. M., Kollmar, O., Piscuoglio, S., & Soysal, S. D. (2025). Immuno-Activated, Highly Expressing PD-1 Phenotype in Hepatocellular Carcinoma Is Associated with a Lower Recurrence Rate. Pathobiology. https://doi.org/10.1159/000543933

Vancouver

Hess GF, Ercan C, Wilhelm A, Zeindler J, Coto-Llerena M, Däster S, et al. Immuno-Activated, Highly Expressing PD-1 Phenotype in Hepatocellular Carcinoma Is Associated with a Lower Recurrence Rate. Pathobiology. 2025. doi:10.1159/000543933

BibTeX
@article{Hess2025,
  author = {Hess, Gabriel F and Ercan, Caner and Wilhelm, Alexander and Zeindler, Jasmin and Coto-Llerena, Mairene and Däster, Silvio and Muenst, Simone and Vosbeck, Jürg and Di Tommaso, Luca and Bolli, Martin and Terracciano, Luigi M and Kollmar, Otto and Piscuoglio, Salvatore and Soysal, Savas D},
  title = {Immuno-Activated, Highly Expressing PD-1 Phenotype in Hepatocellular Carcinoma Is Associated with a Lower Recurrence Rate},
  journal = {Pathobiology},
  year = {2025},
  doi = {10.1159/000543933}
}
Kostenlos starten →